secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001493152-24-043924
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celularity raises FY 2024 net sales guidance to $54-60M; October sales hit record $8.3-8.9M
--------------------------------------------------------------------------------

- Raises full-year 2024 expected net sales guidance to $54M-$60M from $50M-$56M, citing strong advanced biomaterial sales.
- Expected net sales through October 31, 2024: $44.4M ($40.2M advanced biomaterials, $4.2M biobanking); includes ~$9M from new Rebound product.
- October 2024 expected net sales of $8.3M-$8.9M marks highest-ever single-month figure.
- Filed Q2 2024 Form 10-Q on Nov 6, resolving Nasdaq non-compliance notice from Oct 16, 2024.
- Advanced biomaterial product sales for first half 2024 exceeded $24M, surpassing full-year 2023 total.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000149315224043924/0001493152-24-043924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000149315224043924/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-043924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer